Novartis to acquire UK-based Myricx Bio for up to $1.5 billion

Novartis agreed to pay up to $1.5B to acquire U.K.-based biotech Myricx Bio, with deal closure expected in 2H 2026. The transaction signals continued M&A investment in pipeline assets, though near-term financial impact is limited given the deferred closing date.

Analysis

Novartis agreed to pay up to $1.5B to acquire U.K.-based biotech Myricx Bio, with deal closure expected in 2H 2026. The transaction signals continued M&A investment in pipeline assets, though near-term financial impact is limited given the deferred closing date.